FDA’s Data Integrity Issues in Indian Facilities : Pharmaguideline

Online GMP Courses with Certificate


FDA’s Data Integrity Issues in Indian Facilities

Data integrity issues are very common in FDA inspections for Indian pharmaceutical companies and solutions to prevent the issuance of warning letters.
Maintenance of original raw data is a prime responsibility of all pharmaceutical manufacturing units. Data integrity is to maintain the data securely so that only authorized person can edit or delete and changelog must be created for all users. FDA issued seven warning letters related to data integrity issues in 2014.

It is a mandatory requirement of the FDA to maintain the electronic data securely. These days FDA is issuing a lot of warning letters on data integrity issues and companies are unable to maintain the integrity of their data mainly in quality control

FDA Data Integrity Issues in PharmaceuticalsMost of the FDA warning letters and form 483 are issued for failure in data integrity of quality control instruments.

Following issues are commonly found by FDA inspectors during inspections regarding data integrity problems:

1. Backup of Data: In some companies, FDA found that they do not have the facility of data backup and restore. FDA says that all electronic data should be secured and backup should be taken periodically.

Backup data should not be stored in a computer connected to the instrument but it should be stored on the server to make it secure. Data can be stored in the form of CDs or DVDs to make it more secure.

2. Sharing Login IDs: It is seen in many quality control laboratories that some analysts share their login IDs with other analysts. It mixes the work done by the analysts and the analysis done by the individual analyst cannot be identified. FDA doesn’t allow it and rights about it in questions and answers.

3. Audit Trail: In some companies, audit trail function is found in some instruments like HPLC, GC, Spectrophotometer etc. but remains disabled. The audit trail must be active in all instruments those generates electronic data. 21 CFR Part 11 describes details about the audit trail and digital signatures.

4. User Access Rights: Some analysts in quality control have rights to access the analytical data and they can edit or delete it. It is unacceptable to the FDA because analyst can alter the results of the analyzed products. Access rights to delete data should be given to the data reviewer only.

Results of any faulty batch or reanalysis must not be deleted from the system. Everything done on the instrument should be available in instrument log. Analysts should also not have the rights to change the system date and time.

Read the details of warning letters issued by FDA for data integrity issues:

I think this is the time to improve the quality of the inspections of Indian pharmaceutical authorities because domestic product manufacturing companies face difficulties when they go for an FDA inspection. It will harm Indian pharmaceutical export in future because Indian facilities are being warned and banned by FDA.

I invite your views in the comment box on the reasons due to which these top Indian pharmaceutical companies are facing the data integrity issues during the FDA inspections.

Ankur Choudhary is India's first professional pharmaceutical blogger, author and founder of pharmaguideline.com, a widely-read pharmaceutical blog since 2008. Sign-up for the free email updates for your daily dose of pharmaceutical tips.
.moc.enilediugamrahp@ofni :liamENeed Help: Ask Question

3 comments: Post Yours! Read Comment Policy ▼

  1. WELL GOOD INFORMATIVE ARTICLE ,We are very easy to understood ....

  2. Higher management of these companies doesn't have much capabilities. That's why they got warning letters.!

  3. It is good information and easy to understand the article


Please don't spam. Comments having links would not be published.

Popular Categories

QA SOPs QC SOPs Micro SOPs HVAC Production SOPs Stores SOPs Checklists Maintenance SOPs HPLC Sterile GLP Validation Protocols Water System GDP Regulatory Maintenance Calibration Warning Letters Education B.Pharmacy
Online Courses

Follow Pharmaguideline



Editable Pharmaceutical Documents in MS-Word Format. Ready to use SOPs, Protocols, Master Plans, Manuals and more...



Recent Posts